TPG Acquires Pharmatech from Actavis
Ropes & Gray advised global private investment firm TPG on its acquisition from Actavis plc of Actavis’ Aptalis Pharmaceutical Technologies (Pharmatech) business. Pharmatech is a leader in pharmaceutical research and development and manufacturing, with a focus on areas including taste-masking and customized drug release. The deal was announced Feb. 13; financial terms were not disclosed.
The Ropes & Gray team was led by private equity partner Jason Freedman (San Francisco) and included IP transactions partner Mark Bellomy (Boston) and tax partner David Saltzman (Boston).